|
The CAP® cell line, being of human origin, provides recombinant proteins with human-type glycosylation and is commonly employed in the production of recombinant proteins, gene therapy products, and vaccines. CAP® cell line is a CEVEC Pharmaceuticals GmbH core proprietary technology. The kit has been qualified for purification process and in-process lot release testing. This kit has an LOD of ~0.9 ng/ml.
|